| Understanding platinum-induced ototoxicity T Langer, A am Zehnhoff-Dinnesen, S Radtke, J Meitert, O Zolk Trends in pharmacological sciences 34 (8), 458-469, 2013 | 254 | 2013 |
| CNS late‐effects after ALL therapy in childhood. Part III: Neuropsychological performance in long‐term survivors of childhood ALL: Impairments of concentration, attention, and … T Langer, P Martus, H Ottensmeier, H Hertzberg, JD Beck, W Meier Medical and Pediatric Oncology: The Official Journal of SIOP—International …, 2002 | 241 | 2002 |
| High‐dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations T Rau, B Erney, R Göres, T Eschenhagen, J Beck, T Langer Clinical Pharmacology & Therapeutics 80 (5), 468-476, 2006 | 201 | 2006 |
| Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia S Radtke, O Zolk, B Renner, M Paulides, M Zimmermann, A Möricke, ... Blood, the Journal of the American Society of Hematology 121 (26), 5145-5153, 2013 | 199 | 2013 |
| Cardiotoxicity and oncological treatments A Schlitt, K Jordan, D Vordermark, J Schwamborn, T Langer, C Thomssen Deutsches Ärzteblatt International 111 (10), 161, 2014 | 169 | 2014 |
| Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late … RL Mulder, A Font-Gonzalez, MM Hudson, HM Van Santen, EAH Loeffen, ... The Lancet Oncology 22 (2), e45-e56, 2021 | 159 | 2021 |
| CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long‐term survivors of childhood ALL—an evaluation of the interferences between … H Hertzberg, WJ Huk, MA Ueberall, T Langer, W Meier, R Dopfer, ... Medical and Pediatric Oncology: The Official Journal of SIOP—International …, 1997 | 148 | 1997 |
| Ifosfamide‐induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System W Stöhr, M Paulides, S Bielack, H Jürgens, J Treuner, R Rossi, T Langer, ... Pediatric blood & cancer 48 (4), 447-452, 2007 | 145 | 2007 |
| Long-term endocrine and metabolic consequences of cancer treatment: a systematic review J Gebauer, C Higham, T Langer, C Denzer, G Brabant Endocrine Reviews 40 (3), 711-767, 2019 | 138 | 2019 |
| Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany A Pechmann, T Langer, D Schorling, S Stein, S Vogt, U Schara, H Kölbel, ... Journal of neuromuscular diseases 5 (2), 135-143, 2018 | 135 | 2018 |
| 2017 GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors T Simon, B Hero, JH Schulte, H Deubzer, P Hundsdoerfer, ... Klinische Pädiatrie 229 (03), 147-167, 2017 | 128 | 2017 |
| Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer … E Clemens, MM van den Heuvel-Eibrink, RL Mulder, LCM Kremer, ... The Lancet Oncology 20 (1), e29-e41, 2019 | 114 | 2019 |
| Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system W Stöhr, M Paulides, S Bielack, H Jürgens, E Koscielniak, R Rossi, ... Pediatric blood & cancer 48 (2), 140-147, 2007 | 110 | 2007 |
| Klinefelter syndrome and mediastinal germ cell tumors TMK Völkl, T Langer, T Aigner, H Greess, JD Beck, AM Rauch, HG Dörr American Journal of Medical Genetics Part A 140 (5), 471-481, 2006 | 102 | 2006 |
| Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: Almost identical MLL breakpoints in therapy‐related AML after treatment … T Langer, M Metzler, D Reinhardt, S Viehmann, A Borkhardt, M Reichel, ... Genes, Chromosomes and Cancer 36 (4), 393-401, 2003 | 99 | 2003 |
| Models of care for survivors of childhood cancer from across the globe: advancing survivorship care in the next decade ES Tonorezos, D Barnea, RJ Cohn, MS Cypriano, BC Fresneau, R Haupt, ... Journal of clinical oncology 36 (21), 2223-2230, 2018 | 92 | 2018 |
| Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system W Stöhr, T Langer, A Kremers, S Bielack, A Lamprecht-Dinnesen, E Frey, ... Cancer investigation 23 (3), 201-207, 2005 | 84 | 2005 |
| A comparison of genotyping arrays JAM Verlouw, E Clemens, JH de Vries, O Zolk, AJMH Verkerk, ... European Journal of Human Genetics 29 (11), 1611-1624, 2021 | 79 | 2021 |
| Prospective longitudinal evaluation of doxorubicin‐induced cardiomyopathy in sarcoma patients: A report of the late effects surveillance system (LESS) M Paulides, A Kremers, W Stöhr, S Bielack, H Jürgens, J Treuner, ... Pediatric blood & cancer 46 (4), 489-495, 2006 | 78 | 2006 |
| Late effects and long-term follow-up after cancer in childhood T Langer, D Grabow, D Steinmann, B Wörmann, G Calaminus Oncology research and treatment 40 (12), 746-750, 2017 | 67 | 2017 |
